Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2016

View Archived Issues

Discovery of novel benzylpyrazole-based BUB1 kinase inhibitors with antitumor activity

PQR-620 is a novel potent and selective brain-penetrant inhibitor of mTORC1/2

Dimension Therapeutics and PENN enter inherited metabolic disease collaboration

Tokalas initiates phase I study of TK-216 in Ewing's sarcoma

TPX-0005, a novel multi-target inhibitor with the potential to overcome tumor resistance

BIND Therapeutics enters immuno-oncology agreement with Affilogic

VX-745 significantly improves motor and sensorial functionality in stroke model

Monoclonal antibody targeting Chikungunya virus --SVIR-001-- reduces viral load in primate model

Phase I data support further evaluation of plasma kallikrein inhibitor KVD-001

Paraza Pharma, Syros Pharmaceuticals and WuXi PharmaTech disclose CDK7 inhibitors

RegeneRx Biopharmaceuticals reports results from RGN-259 phase II/III study

Chembio updates progress in development of point-of-care diagnostic test for Zika virus in Brazil

Immunovaccine launches immunotherapy program

Esteve and PCB strengthen their collaboration for the discovery of new analgesic agents

Novo Nordisk reports pipeline highlights of first quarter 2016

Wyss Institute leads collaborators in development of paper-based diagnostic system for Zika

Ovarian cancer Consortium for Long-Term Survival receives phase II funding

Halaven receives approval in Europe for treatment of advanced liposarcoma

Baxalta launches a recombinant blood coagulant factor IX agent in Japan

New joint venture formed to focus on obtaining Chinese approval for Dance-501

Encouraging first clinical results reported for cancer gene therapy SGT-94

Intarcia Therapeutics presents ITCA-50 clinical results

Takeda partners with Gates Foundation on polio vaccine for developing countries

PureTech Health launches immuno-oncology company Vor BioPharma

Allergy Therapeutics reports topline phase II data on Pollinex Quattro Birch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...